For the quarter ending 2025-09-30, GALT has $12,865K in assets. $136,445K in debts. $11,525K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 11,525 | 13,771 | ||
| Prepaid expenses and other current assets | 1,204 | 1,656 | ||
| Total current assets | 12,729 | 15,427 | ||
| Other assets | 136 | 175 | ||
| Total assets | 12,865 | 15,602 | ||
| Accounts payable | 5,390 | 5,865 | ||
| Accrued expenses and other | 5,038 | 4,846 | ||
| Accrued dividends payable | 0 | 63 | ||
| Convertible notes payable and accrued interest, net of discounts related party (note 3) | 32,521 | 0 | ||
| Derivative liabilities (note 4) | 3,742 | 0 | ||
| Borrowing and accrued interest under convertible lines of credit, net of debt discount related party (note 9) | 89,754 | - | ||
| Total current liabilities | 136,445 | 10,774 | ||
| Convertible notes payable and accrued interest, net of discounts related party (note 3) | 0 | 32,308 | ||
| Derivative liabilities (note 4) | 0 | 1,537 | ||
| Borrowing and accrued interest under convertible lines of credit, net of debt discount related party (note 9) | 0 | 88,150 | ||
| Total liabilities | 136,445 | 132,769 | ||
| Series c super dividend redeemable convertible preferred stock 1,000 shares authorized, 176 shares issued and outstanding at september 30, 2025 and december 31, 2024, redemption value 8,018,000, liquidation value 1,760,000 at september 30, 2025 | 1,723 | 1,723 | ||
| Series a 12 convertible preferred stock 1,742,500 shares authorized, 1,210,000 and 1,235,000 issued and outstanding at september 30, 2025 and december 31, 2024, respectively, liquidation value 1,210,000 at september 30, 2025 | 490 | 490 | ||
| Common stock, 0.001 par value 150,000,000 shares authorized at september 30, 2025 and december 31, 2024, 64,472,792 and 63,157,235 issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 64 | 63 | ||
| Additional paid-in capital | 301,127 | 299,318 | ||
| Retained deficit | -426,984 | -418,761 | ||
| Total stockholders deficit | -125,303 | -118,890 | ||
| Total liabilities, redeemable convertible preferred stock and stockholders deficit | 12,865 | 15,602 | ||
GALECTIN THERAPEUTICS INC (GALT)
GALECTIN THERAPEUTICS INC (GALT)